Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease (STARLIGHT)

• ClinicalTrials.gov Identifier: NCT05417126
• Recruitment Status: Completed
• First Posted: June 14, 2022
• Last Update Posted: November 9, 2023
• Sponsor: Nanoscope Therapeutics Inc.
• Information provided by (Responsible Party): Nanoscope Therapeutics Inc.

Tracking Information

• First Submitted Date: June 9, 2022
• First Posted Date: June 14, 2022
• Last Update Posted Date: November 9, 2023
• Actual Study Start Date: July 5, 2022
• Actual Primary Completion Date: August 2, 2023 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: June 9, 2022)

Type, severity, and incidence of ocular and systemic adverse events (AEs) [ Time Frame: 48 weeks ]

Type, severity, and incidence of ocular and systemic adverse events (AEs), specifically those related to intravitreal injection of vMCO-010

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: June 13, 2022)

• Effect of vMCO-010 as assessed by visual acuity [ Time Frame: 48 weeks ]
  Change from baseline in BCVA at Weeks 12, 24, 48 in the study eye and the fellow eye
• Effect of vMCO-010 on Light-guided Mobility [ Time Frame: 48 Weeks ]
  Change from baseline in Multi-Luminance Mobility Test at weeks 12, 24, 48 in the study eye and the fellow eye
• Effect of vMCO-010 on determination of shape [ Time Frame: 48 Weeks ]
  Change from baseline in accuracy in determination of shape using Low Vision Multi-Parameter Test (LVMPT) at weeks 12, 24, 48 in the study eye and the fellow eye
• Effect of vMCO-010 on determination of optical flow [ Time Frame: 48 Weeks ]
  Change from baseline in accuracy in determination of optical flow using the LVMPT at weeks 12, 24 and 48 in the study eye and the fellow eye

Original Secondary Outcome Measures (submitted: June 9, 2022)

• To evaluate the effect of vMCO-010 as assessed by visual acuity [ Time Frame: 48 weeks ]
  Change from baseline in BCVA at Weeks 12, 24, 48 in the study eye and the fellow eye
• To evaluate the effect of vMCO-010 on Light-guided Mobility [ Time Frame: 48 Weeks ]
  Change from baseline in Multi-Luminance Mobility Test at weeks 12, 24, 48 in the study eye and the fellow eye
• To evaluate the effect of vMCO-010 on determination of shape [ Time Frame: 48 Weeks ]
  Change from baseline in accuracy in determination of shape using Low Vision Multi-Parameter Test (LVMPT) at weeks 12, 24, 48 in the study eye and the fellow eye
• To evaluate the effect of vMCO-010 on determination of optical flow [ Time Frame: 48 Weeks ]
  Change from baseline in accuracy in determination of optical flow using the LVMPT at weeks 12, 24 and 48 in the study eye and the fellow eye

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
• Official Title: A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
• Brief Summary: The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
• Detailed Description: This multicenter open label study will evaluate single dose level of vMCO-010 in up to 6 subjects with Stargardt's Disease. Subjects with documented clinical diagnosis of Stargardt disease (classic fleck phenotype and/or well-demarcated sub-foveal area of significantly reduced autofluorescence as imaged by FAF), or genetic diagnosis with pathogenic variants in ABCA4, ELOVL4, or PROM 1. All subjects will continue to be assessed for 48 weeks following treatment with vMCO-010.
• Study Type: Interventional
• Study Phase: Phase 2

Study Design

Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

6 subjects will be enrolled for vMCO-010 treatment

Masking: None (Open Label)
Primary Purpose: Treatment

• Condition: Stargardt Disease

Intervention

Biological: Gene Therapy-vMCO-010

The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

Study Arms

Experimental: Experimental-vMCO-010

Participants receive 1.2E11gc/eye of vMCO-010

Intervention: Biological: Gene Therapy-vMCO-010

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: June 9, 2022): 6
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: September 28, 2023
• Actual Primary Completion Date: August 2, 2023 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. ≥16 years of age
2. Able to comprehend and give informed consent.
3. Able to comply with testing and all protocol tests.
4. Documented clinical diagnosis of Stargardt disease (classic fleck phenotype and/or well-demarcated sub-foveal area of significantly reduced autofluorescence as imaged by FAF), or genetic diagnosis with pathogenic variants in ABCA4, ELOVL4, or PROM1
5. In the study eye: ETDRS BCVA in range of 1.3 logMAR (Approximate Snellen equivalent: 20/400) to 1.9 logMAR (Snellen equivalent: 20/1600), and ETDRS BCVA no better than 20/200 in the fellow eye.
6. Presence of retinal inner nuclear and nerve fiber layers on optical coherence tomography (OCT) testing in the study eye at screening

Exclusion Criteria:

1. Presence of any concurrent ocular disease that would affect study outcomes (e.g., severe cataracts; subjects can be enrolled 3 months after successful cataract surgery).
2. Received any of the following treatments: gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips (such as ARGUS-II) or sub-retinal injections.
3. Has taken non-approved items (supplement containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) over the past 30 days
4. Participation in an interventional study of a vitamin A derivative ≤ 3 months prior to screening
5. Presence of significant cardiovascular or cerebrovascular disease, including stroke within 12 months of entry.
6. Resting heart rate outside specified limits upon repeated measurement.
7. History of uncontrolled diabetes, hepatitis, pancreatitis, cirrhosis, liver failure, uncontrolled thyroid disease or hypervitaminosis A.
8. Any intraocular surgery or thermal laser within 3 months of trial entry or any prior thermal laser in the macular region.
9. Any major surgical procedure within one month of trial entry or anticipated during the trial.
10. Clinically significant abnormal lab results at screening
11. Known serious allergies to the fluorescein dye used in angiography or intraocular pressure measurement, povidone iodine, or to the components of the vMCO-010 formulation
12. In the Investigator's opinion, any severe acute or chronic medical condition, psychiatric condition, physical examination finding or laboratory abnormality
13. Pre-existing conditions in the study eye such as glaucoma, diseases affecting the optic nerve causing significant visual field loss, history of uveitis, corneal or lenticular opacities).
14. Presence of any complicating systemic diseases such as malignancies whose treatment could affect central nervous system function..
15. Subjects who are positive for syphilis, hepatitis B, C, and human immunodeficiency virus (HIV) will be excluded..
16. Presence of narrow iridocorneal angles contraindicating pupillary dilation in the study eye.
17. Presence of disorders of the ocular media in the study eye which could interfere with visual acuity and other ocular assessments, including OCT, during the study period.
18. Presence of macular hole in the study eye, evident by ophthalmoscopy and/or by OCT examinations
19. Current evidence of retinal detachment in the study eye assessed by the Investigator that significantly affects central vision.
20. Current use of hydroxychloroquine, chloroquine, or any related retina-toxic compounds.
21. Active ocular inflammation or recurrent history of idiopathic or autoimmune associated uveitis.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 16 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT05417126
• Other Study ID Numbers: NTXMCO-004
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: The results of the clinical trial will be made available when the study is completed. The results will be published on this site and be available to conference presentations and publications.
• Time Frame: Within 12 Months of study completion
• Access Criteria: Safety and efficacy Results

• Current Responsible Party: Nanoscope Therapeutics Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: Nanoscope Therapeutics Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Dr Samarendra Mohanty; Nanoscope Therapeutics Inc.

• PRS Account: Nanoscope Therapeutics Inc.
• Verification Date: November 2023